- sodium cromoglicate
This information is intended for use by health professionals
Sodium Cromoglicate 2% w/v Eye Drops, Solution
Each ml of eye drops contains
Active substance: 20 mg sodium cromoglicate (2.0% w/v), (one drop contains 0.7mg sodium cromoglicate).
Excipient: 0.1mg benzalkonium chloride
For a full list of excipients, see section 6.1.
Eye Drops, Solution
Clear colourless to pale yellow solution
For the relief and treatment of seasonal and perennial allergic conjunctivitis.
Adults and Children over 6 years:
One or two drops to be administered into each eye four times daily.
Children under 6 years
There is no relevant indication for use of sodium cromoglicate in children. Sodium cromoglicate is contraindicated in children under 2 years of age.
There is no evidence to suggest that dosage alteration is required for elderly patients.
Hypersensitivity to the active substance or to any of the excipients
Discard any remaining contents four weeks after opening the bottle.
Sodium cromoglicate eye drops contains benzalkonium chloride.
May cause eye irritation.
Avoid contact with soft contact lenses.
Remove contact lenses prior to application and wait at least 15 minutes before reinsertion.
Known to discolour soft contact lenses.
No interaction studies have been performed.
It is not known whether sodium cromoglicate has any effect on fertility.
As with all medication, caution should be exercised especially during the first trimester of pregnancy. Cumulative experience with sodium cromoglicate suggests that it has no adverse effects on fetal development. It should be used in pregnancy only where there is a clear need.
It is not known whether sodium cromoglicate is excreted in human breast milk but, on the basis of its physicochemical properties, this is considered unlikely. There is no information to suggest the use of sodium cromoglicate has any undesirable effects on the baby.
Sodium cromoglicate may interfere with the ability to drive and use machines.
Instillation of these eye drops may cause a transient blurring of vision. Patients are advised not to drive or operate machinery if affected, until their vision returns to normal.
Transient stinging and burning may occur after instillation. Other symptoms of local irritation have been reported rarely.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdosage is very unlikely. In the event of accidental ingestion, symptomatic treatment is recommended.
Pharmacotherapeutic group: , ATC code: under application/pending
The solution exerts its effect locally in the eye.
In vitro and in vivo animal studies have shown that sodium cromoglicate inhibits the degranulation of sensitised mast cells which occurs after exposure to specific antigens. sodium cromoglicate acts by inhibiting the release of histamine and various membrane derived mediators from the mast cell.
Sodium cromoglicate has demonstrated the activity in vitro to inhibit the degranulation of non-sensitised rat mast cells by phospholipase A and subsequent release of chemical mediators. sodium cromoglicate did not inhibit the enzymatic activity of released phospholipase A on its specific substrate.
Sodium cromoglicate has no intrinsic vasoconstrictor or antihistamine activity.
Sodium cromoglicate is poorly absorbed. When multiple doses of sodium cromoglicate ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of sodium cromoglicate is absorbed into the systemic circulation (presumably by way of the eye, nasal passages, buccal cavity and gastrointestinal tract). Trace amounts (less than 0.01%) of the sodium cromoglicate does penetrate into the aqueous humour and clearance from this chamber is virtually complete within 24 hours after treatment is stopped.
In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of sodium cromoglicate is absorbed following administration to the eye.
Sodium cromoglicate is not metabolised.
There are no data of relevance to the prescriber that are not already included elsewhere in the SmPC.
Water for Injections
After first opening the bottle: 4 weeks
Discard any remaining solution four weeks after first opening.
Before first opening the bottle: This medicinal product does not require any special storage conditions
After first opening the bottle: Do not store above 25°C.
LDPE Blow Fill Seal (BFS) container with white polypropylene spiked screw cap having a tamper-proof base ring.
Pack sizes: 1x5ml and 1x10ml
Not all pack sizes may be marketed.
No special requirements
Opening the dropper container before first use
Note: Do not use the bottle if the tamper-proof base ring with cap is broken before you first use it.
1. Turn the cap in counter clockwise direction. This will break the tamper-proof base ring (Fig.1).
2. Remove the tamper-proof base ring by retaining the cap on the container (Fig.2).
3. Tighten the cap on the nozzle so that the edge of the cap and the edge of
bottle neck are totally aligned. Turning the screw cap clockwise will pierce the tip of the dropper container. (Fig.3).
4. To open the dropper container, remove the cap by turning it in the counter clockwise direction (Fig.4).
5. Tighten the cap on the container after every use (Fig.5).
Brown & Burk UK Ltd5, Marryat CloseHounslow WestMiddlesexTW4 5DQUK
29/03/2012 / 21/02/2016
6-9 The Square, Regus Stockley Business Park, Uxbridge, UB11 1FW, UK
+44 (0)203 384 7188
+44 (0)203 384 7188
+44 (0)203 384 7188
+44 (0)203 384 7188